Back to search
FDAFDA · Food and drugs·Recall number D-0291-2025

Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), Rx Only, 100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each) per carton, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 51079-443-20.

Published March 26, 2025 · Recall initiated: March 7, 2025

Summary

FDA records drug Class II recall D-0291-2025, published March 26, 2025 and initiated March 7, 2025. Recalling firm: Mylan Institutional, Inc.; Status: Ongoing; Reported quantity: 1,068 cartons; Lot: Lot 3115773, Exp. 03/31/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Super-Potent Drug: Out of specification potency results were obtained.

What to do

Voluntary: Firm initiated · Letter

Get an email if LEVOTHYROXINE SODIUM has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
LEVOTHYROXINE SODIUM
Manufacturer
Mylan Institutional, Inc.
Distributor
Nationwide in the USA
Lot
Lot 3115773, Exp. 03/31/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), Rx Only, 100 Unit Dose Blister Cards of 10 (10 cards of 10 tablets each) per carton, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, Made in India, NDC 51079-443-20. recalled?

Yes. FDA published recall D-0291-2025 on March 26, 2025. Reported hazard: Super-Potent Drug: Out of specification potency results were obtained.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: LEVOTHYROXINE SODIUM.